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Recommendations
There is no evidence that conflicts with the previous 
recommendations published in the original version of the 
“Guidelines for the performance of fusion procedures for 
degenerative disease of the lumbar spine.”
Grade B
There is Level I evidence (single study) to recommend 
the use of a circumferential fusion (ALIF + posterolateral 
fusion) as a more cost-effective option (over an 8-year 
time period) than stand-alone posterolateral fusion.
There is Level I evidence (single study) to recom-
mend either total lumbar disc replacement (TDR) or lum-
bar fusion from an economic perspective for the treat-
ment of selected patients with chronic low back pain (over 
a 2-year time period).
Grade C
With respect to the combination of anterior lumbar 
interbody fusion (ALIF) plus posterolateral fusion, there 
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A comprehensive economic analysis generally involves the calculation of indirect and direct health costs from 
a societal perspective as opposed to simply reporting costs from a hospital or payer perspective. Hospital charges for 
a surgical procedure must be converted to cost data when performing a cost-effectiveness analysis. Once cost data 
has been calculated, quality-adjusted life year data from a surgical treatment are calculated by using a preference-
based health-related quality-of-life instrument such as the EQ-5D. A recent cost-utility analysis from a single study 
has demonstrated the long-term (over an 8-year time period) benefits of circumferential fusions over stand-alone 
posterolateral fusions. In addition, economic analysis from a single study has found that lumbar fusion for selected 
patients with low-back pain can be recommended from an economic perspective. Recent economic analysis, from 
a single study, finds that femoral ring allograft might be more cost-effective compared with a specific titanium cage 
when performing an anterior lumbar interbody fusion plus posterolateral fusion.
(http://thejns.org/doi/abs/10.3171/2014.4.SPINE14259)
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Abbreviations used in this paper: ALIF = anterior lumbar inter-
body fusion; CCR = cost-to-charge ratio; CMS = Center for Medi-
care and Medicaid Services; CPT = Current Procedural Terminolo-
gy; DRG = Diagnosis-Related Group; FRA = femoral ring allograft; 
HR-QOL = health-related quality of life; ICBG = iliac crest bone 
graft; ICD = International Classification of Diseases; ICER = incre-
mental cost-effectiveness ratio; LOS = length of hospital stay; MIS 
= minimally invasive surgery; ODI = Oswestry Disability Index; 
QALY = quality-adjusted life year; rhBMP-2 = recombinant human 
bone morphogenetic protein–2; SEK = Swedish kronor; SF-36 = 
36-Item Short Form Health Survey; SPORT = Spine Patient Out-
comes Research Trial; TC = titanium cage; TDR = total lumbar disc 
replacement; TLIF = transforaminal lumbar interbody fusion; UK = 
United Kingdom; VAS = visual analog scale.
Part 3: Assessment of economic outcome
15J Neurosurg: Spine / Volume 21 / July 2014
is Level II evidence that the use of a femoral ring allograft 
for interbody fusion is a more cost-effective interbody op-
tion than the use of a specific titanium cage.
From an economic perspective, both iliac crest bone 
graft and recombinant human bone morphogenetic pro-
tein–2 (rhBMP-2) are posterolateral fusion graft options 
in patients over the age of 60 (Level IV evidence).
From an economic perspective, both minimally in-
vasive and open transforaminal lumbar interbody fusion 
(TLIF) techniques are options when treating patients 
with symptomatic Grade I degenerative spondylolisthesis 
(Level IV evidence).
Grade I
There are conflicting data regarding the cost-effec-
tiveness of cell-salvage auto-transfusion as an adjunct to 
lumbar fusion (Level IV evidence).
Rationale
Ongoing changes in national health care policy have 
created an increased awareness on medical resource allo-
cation and greater emphasis on cost-benefit analyses. As 
part of the American Recovery and Reinvestment Act of 
2009, the federal government has allocated $1.1 billion 
in funds toward comparative-effectiveness research.9,23 
An area of specific interest has been the application of 
lumbar fusion in the management of degenerative spine 
disease, with a focus on establishing clinical efficacy and 
cost-effectiveness.31 Management of chronic degenerative 
spinal conditions in the United States is estimated to cost 
nearly $85 billion annually, with a significant percent-
age attributed to the dramatic increase in the frequency 
of lumbar fusion procedures.13,15,25 In 2004, more than 
300,000 spinal fusions were performed in the US, ac-
counting for more than $16 billion in hospital charges 
alone.14 Advances in surgical fusion technologies have 
improved the surgeon’s ability to attain a solid arthrod-
esis and expand the treatment options available for pa-
tients with spine disorders. Since the initial publication of 
the Lumbar Fusion Guidelines, there is recognition that 
the evolution of devices and techniques for lumbar fusion 
impacts not only surgical outcomes but also health care 
costs. The purpose of this qualitative review is to evaluate 
current research that examines the economic impact of 
lumbar fusion on the management of degenerative lumbar 
spine disease. The expense of fusion surgery and new fu-
sion technologies must be weighed against the incremen-
tal improvement in patient outcomes and quality of life.
Search Criteria
A search of the National Library of Medicine data-
base of literature was performed with limits: ((“2002” 
[PDAT]: “2011”[PDAT]) AND English[lang]). Using the 
following terms: (“lumbar” AND “fusion”[All Fields]) 
yielded 4002 citations. The following terms were com-
bined: (“lumbar” AND “fusion” AND “outcomes”[All 
Fields]), which yielded 807 citations and (“lumbar” AND 
“fusion” AND “cost”[All Fields]) which yielded 154 cita-
tions. The titles and abstracts of the 154 articles were re-
viewed. In addition, additional searches were performed 
with terms: ((“lumbar fusion”[MeSH]) AND (“cost ef-
fective ness”[MeSH]) OR (“employment status”[MeSH]), 
(“mortality”) OR (“medical care costs[MeSH])” OR (“cost 
containment”[MeSH] OR “cost comparison”[MeSH]) OR 
(“spondylolisthesis”)). Of the articles reviewed, 13 clinical 
series focusing on adult patients who underwent lumbar fu-
sion procedures were selected based on the inclusion of an 
economic analysis.
A comprehensive economic analysis from a societal 
perspective that included multivariate sensitivity analy-
ses was performed in 4 articles.16,18,36,39 A cost analysis 
investigating various surgical approaches for lumbar 
fusion was performed in 1 study.36 Another study per-
formed a cost analysis on the type of interbody device 
used in lumbar fusion.16 Two randomized trials compared 
outcomes and cost of lumbar fusion to conservative man-
agement.19,39 Two studies examined the comparative cost-
effectiveness of minimally invasive versus open TLIF.43,44 
One preliminary study provided cost-effectiveness data 
for TLIF procedures.1 Six studies addressed incremen-
tal cost-effectiveness of new technology for lumbar fu-
sion.2,7,8,20,30,34
Scientific Foundation
A cost-utility analysis is a specific type of cost-effec-
tiveness evaluation that allows a comparison of 2 alterna-
tive treatment strategies in terms of the cost required for 
a given clinical outcome. These analyses are measured 
in terms of quality-adjusted life years (QALYs) gained, 
taking into account both the quantity and quality of life 
resulting from a given intervention.21,32 For calculation of 
QALYs, patients must be surveyed using a preference-
based health-related quality-of-life (HR-QOL) outcome 
instrument, such as the EQ-5D (EuroQol Group).29,37 An-
other commonly used preference-based HR-QOL instru-
ment is the SF-6D,4 which consists of 11 items selected 
from the 36-Item Short Form Health Survey (SF-36).5 An 
HR-QOL score is converted to a “health utility,” typically 
a number on a continuum between 0, indicating death, 
and 1, indicating perfect health. Negative values can be 
generated when conditions considered worse than death 
exist.38 A QALY is determined by the number of years 
in a given health state multiplied by the utility score as-
signed to that particular health state. A single year spent 
in perfect health is given the value of 1 QALY.
When comparing 2 treatment strategies, A and B, it is 
necessary to know the incremental cost-utility ratio (simi-
lar to the incremental cost-effectiveness ratio [ICER]). 
The ICER of Treatment B versus A is calculated as: 
(Cost of B − Cost of A)/(QALYs gained from B − QALYs 
gained from A).
From this calculation, the incremental cost of each 
additional QALY is determined when Treatment B is 
chosen over Treatment A. The acceptable cost per addi-
tional QALY represents society’s willingness to pay and 
serves as a foundation for cost-effectiveness analyses. 
Since 1982, $50,000 per QALY gained has been cited as 
the threshold for a cost-effective intervention,42 although 
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more recent proposals argue for a cut-off value closer to 
$100,000 or more, reflecting inflation and increased costs 
for research and development.3
There are 3 main categories of cost: direct, indirect, 
and intangible. Direct costs are resources that are con-
sumed by the surgical procedure (i.e., operating room 
supplies, surgeon time and labor, cost of hospital stay). 
Indirect costs generally refer to a loss of productivity due 
to the morbidity or mortality of the surgical procedure. 
For example, the amount of work missed by the patient 
and/or their caretaker during the recovery period would 
qualify as indirect costs. Intangible costs include the pain 
and suffering from the surgical procedure. Both the indi-
rect and the intangible costs are often difficult to quantify 
in monetary terms. Therefore, the total cost of a surgical 
procedure is based on the quantity of resources used and 
the assignment of cost to these resources. Determining 
the quantity of resources used is relatively straightfor-
ward for a surgical procedure. However, unit costs may 
vary between different countries, geographic regions, 
time periods, or hospitals. The cost perspective (“costs to 
whom”) must be considered and expressly stated in any 
economic analysis. Costs to the patient for an intervention 
may be quite different from those to a hospital, a third-
party payer, or to society itself.
Several methods have been introduced to estimate 
the total cost of a surgical procedure. One method uti-
lizes the total hospital charge for the procedure and ad-
mission. The hospital charge is based on several data 
coding systems that are currently used to determine 
reimbursement, including the diagnosis-related group 
(DRG), International Classification of Diseases (ICD) 
system, and current procedural terminology (CPT) sys-
tem.10,12,33,45 This method, however, fails to reflect the ac-
tual amount of reimbursement received by the hospital 
or physician, or the actual costs, counting instead upon 
charges as a surrogate for costs. For the hospital charges 
of different centers to be used as a proxy for direct costs, 
a cost-to-charge ratio (CCR) must be calculated and ap-
plied. The CCR is specific for every hospital, for many 
departments within the hospital, and for a given time pe-
riod. The CCR is calculated from Medicare Hospital Cost 
Reports (Worksheet C or D) in combination with claims 
data. Although obtaining CCRs is labor intensive, it has 
been suggested that this approach is the most accurate 
way to determine actual “cost” when comparing different 
centers.17 Other methods for calculating cost of a surgical 
procedure include using total Medicare charges allowed, 
or the Medicare reimbursement. The most common and 
simplest way to estimate the direct cost for a procedure 
is using Medicare payments.35,41 Real hospital costs can 
also be estimated by using the Center for Medicare and 
Medicaid Services (CMS) reimbursement value for DRG 
and CPT codes.
Micro-costing methodology involves measuring all 
the costs and benefits of a treatment as accurately as pos-
sible. It becomes particularly useful when evaluating and 
comparing regional differences in the resource utiliza-
tion for a particular surgical procedure. However, micro-
costing analysis is expensive and time-consuming due to 
extensive record keeping and database management. Of-
ten details, specific to a single institution, limit the gen-
eralizability of the conclusions. Finally, there are some 
elements of the micro-costing analysis that inevitably re-
quire estimation, which will also compromise the validity 
of the conclusions.28
An understanding of the methodology used to de-
termine cost is critical when interpreting the results and 
conclusions of a study.11 For example, in the recent Spine 
Patient Outcomes Research Trial (SPORT), the cost-ef-
fectiveness of surgery relative to nonoperative treatment 
for lumbar disc disease was $69,403/QALY using overall 
adult surgery costs (all payers), but only $34,355/QALY 
using Medicare population–specific surgery costs.40 Us-
ing Medicare-based reimbursements will significantly 
lower the estimate of medical costs for any given treat-
ment, which may be appropriate in older aged individu-
als, but irrelevant when considering younger patients with 
better (e.g., Workers Compensation) or worse (e.g., Med-
icaid) reimbursements.
Literature Review
Comparison of Lumbar Fusion to Nonoperative Therapy
Utilizing 2-year follow-up data from the SPORT 
study, Tosteson et al. investigated the cost-effectiveness 
of lumbar fusion for patients with degenerative spon-
dylolisthesis and spinal stenosis.39 Patients underwent 
nonoperative treatment, decompressive laminectomy, or 
laminectomy with fusion, with or without instrumenta-
tion and/or iliac crest bone graft. QALYs were calculated 
from EQ-5D scores at baseline, 6 weeks, and 3, 6, 12, and 
24 months following treatment. Direct and indirect costs 
were collected prospectively based on 2004 Medicare 
payments. Operative management of spinal stenosis im-
proved health significantly compared with nonoperative 
care, 0.17 QALYs gained, at a cost of $77,600 per QALY. 
Operative management of degenerative spondylolisthesis, 
93% of which were lumbar fusions, provided significant 
benefit, with 0.23 QALYs gained at a cost of $115,600 per 
QALY. Although $115,600 is greater than the accepted 
societal expense per QALY, it is much less than previ-
ous estimates. Kuntz et al. reported that an instrumented 
lumbar fusion procedure cost $3,112,800 per QALY and 
instead favored noninstrumented fusion with a compara-
tive medical benefit.24 Although Tosteson et al. performed 
a rigorous cost analysis, the underlying heterogeneity of 
the study population and surgical techniques limits the 
validity of the study conclusions. In addition, follow-up 
data beyond 2 years will be essential to order to formulate 
meaningful recommendations regarding the cost-effec-
tiveness of lumbar fusion over nonfusion treatments for 
lumbar degenerative disorders. This study provides Level 
II evidence that surgery for degenerative spondylolisthe-
sis is effective but more costly than surgery for spinal ste-
nosis (see Table 1).
Fritzell et al. performed a randomized controlled 
trial of patients with chronic low-back pain who under-
went either lumbar fusion or nonoperative treatment.19 
Two hundred eighty-four patients from multiple centers 
were randomized, and outcomes were measured by the 
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Oswestry Disability Index (ODI) and visual analog scale 
(VAS) for 2 years. Patients who underwent surgery had 1 
of 3 procedures: noninstrumented posterolateral fusion, 
instrumented posterolateral fusion, or a posterolateral 
circumferential fusion with pedicle screws and interbody 
grafts. Both direct and indirect costs were collected for 
each treatment group. The mean cost per patient was sig-
nificantly higher in the surgical group (cost in Swedish 
kronor [SEK]: SEK 123,000 [US$18,731]) compared with 
the nonoperative group (SEK 65,200 [US$9929]). A sig-
nificantly greater percentage of patients in the surgically 
treated group returned to part-time or full-time work 
compared with the nonoperative group (33% vs 16%, p = 
0.015). Overall, lumbar fusion was associated with signif-
icantly greater improvements in pain and function com-
pared with nonoperative treatment at 2 years. However, 
there was no difference in clinical outcome between the 
3 fusion techniques studied. Compared with noninstru-
mented posterolateral fusion, the placement of pedicle 
screws increased hospital costs by 66% and a circum-
ferential fusion procedure increased them by 103%. This 
study, however, did not measure QALYs, and therefore, 
it is difficult to interpret and generalize the data against 
more meaningful cost analyses.26 Another significant 
limitation of this study is that the retrospective nature of 
the cost analysis, introducing the potential for significant 
recall bias regarding the patient’s recollection of outpa-
tient health resource utilization. Due to these design limi-
tations, no definite conclusions regarding cost-effective-
ness can be formulated from this economic analysis. It 
provides Level III evidence that outcomes are improved 
with fusion surgery for low-back pain compared with 
nonoperative treatment (see Table 1).
Lumbar Disc Arthroplasty Versus Posterior Lumbar Fusion
Fritzell’s group performed a randomized controlled 
trial comparing the cost-effectiveness of total lumbar 
disc replacement (TDR) versus posterolateral fusion with 
or without interbody fusion.18 One hundred fifty-two pa-
tients with chronic low-back pain were randomized to 
receive either TDR (80 patients) or fusion (72 patients). 
QALY outcomes were assessed using EQ-5D over a 
2-year time period. Direct and indirect health costs were 
collected. Utilization of all outpatient resources and loss 
of work productivity were included to calculate health 
costs from a societal perspective. Multi-way sensitivity 
analyses were performed on excluding reoperations in 
both groups, costs for inpatient rehabilitation, and health 
cost discounting (see Table 1).
Follow-up data were available on 99% of cases at 2 
years. From a societal perspective the mean health cost 
for TDR was SEK 599,560 (US$90,162) and for lumbar 
fusion was SEK 685,919 (US$103,149). This difference 
in cost was not statistically significant. At 2 years after 
surgery both groups demonstrated an improvement of 0.4 
QALYs. The study’s authors concluded that lumbar TDR 
and lumbar fusion have similar cost-effectiveness pro-
files in Sweden, although TDR was associated with lower 
costs from a health care perspective because of a lower 
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Circumferential Lumbar Fusion Versus Posterolateral 
Lumbar Fusion
Soegaard et al. randomized 146 patients with chronic 
low-back and leg pain to either posterolateral or circum-
ferentially instrumented fusion and followed outcomes 
for 4–8 years after surgery.36 Outcomes were measured 
with EQ-5D, SF-36, ODI, and pain scores. Service uti-
lization (i.e., surgery, reoperations, rehospitalizations, 
general practitioner visits, etc.) was recorded per patient 
by the National Patient Registry in Denmark. Service uti-
lization is valued by national average unit costs through 
the DRG system of coding. A micro-costing analysis was 
performed, including patient costs, medications, and pro-
ductivity costs. The circumferentially treated group dem-
onstrated better functional outcome (p = 0.004), higher 
fusion rate (p < 0.04), and fewer reoperations (15% versus 
38%) compared with the posterolateral cohort. From a 
societal perspective, the circumferentially treated group 
demonstrated significantly lower costs compared with 
the posterolateral group (p = 0.012), primarily due to 
the higher reoperation rate and lower return to work rate 
observed in the posterolateral group. This study showed 
an incremental savings of $49,306 per QALY following 
a circumferential fusion compared with a posterolateral 
fusion. The study benefited from the long follow-up in-
terval, large number of patients enrolled, and the com-
prehensive National Patient Registry. However, there are 
limitations, which include the heterogeneous population 
of patients with respect to presenting diagnosis and his-
tory of previous spine surgery. For example, patients with 
isthmic spondylolisthesis may have more favorable out-
comes following lumbar fusion than other patients under-
going a lumbar fusion for different reasons. This study 
provides Level I evidence that circumferential fusion 
through a posterolateral approach is more cost-effective 
than stand-alone posterolateral fusion for up to 8 years 
following surgery (see Table 1).
Minimally Invasive Versus Open TLIF
Two retrospective studies by Wang et al. have ad-
dressed the cost-effectiveness of minimally invasive ver-
sus open TLIF.43,44 In a retrospective review of 59 single-
level TLIF cases at one institution using hospital charges 
as a surrogate for hospitalization costs, Wang and col-
leagues found that minimally invasive single-level TLIF 
was associated with lower hospital charges ($70,159) 
compared with open single-level TLIF ($78,444) (p = 
0.027). Using the Nationwide Inpatient Sample (6106 cas-
es) and applying CCRs to estimate hospital costs, Wang et 
al. found that minimally invasive single-level fusion was 
associated with hospital costs similar to those for open 
TLIF; however, for 2-level procedures, hospital costs of 
minimally invasive TLIF procedures ($33,879) were low-
er than costs of open surgery ($35,984; p = 0.0023). Nei-
ther study included outcome measures, so ICERs could 
not be calculated to assess cost-effectiveness (see Table 1).
A recent preliminary study reported cost-effective-
ness data for TLIF using EQ-5D to measure QALYs 
gained over a 2-year time period. Adogwa et al. calcu-
lated health costs from a societal perspective by includ-
ing inpatient and outpatient Medicare costs as well as 
workday losses.1 While this type of analysis was limited 
because there was no comparison group, the results dem-
onstrated that TLIF might be cost-effective ($42,854/ 
QALY). Comparative studies are needed to calculate IC-
ERs to validate these findings (see Table 1).
Type of Interbody Device Used for Lumbar Interbody  
Fusion
Freeman et al. randomized 83 patients with chronic 
low-back pain undergoing circumferential fusion to re-
ceive either a titanium cage (TC) or femoral ring allograft 
(FRA) in an effort to determine which interbody graft 
was more cost-effective.16 Outcomes were measured by 
ODI and SF-6D at various intervals for up to 2 years 
following surgery. Direct cost data were derived from 
the National Health Service, using local center-specific 
unit costs for individual health resources. The indirect 
costs were measured by the human capital approach, 
which is based on the total expected production losses 
for an individual worker for the duration of disability.22 
The cost of TC was approximately 10 times higher than 
FRA (£1609.76 [US$2583] vs £158.92 [US$255]), and the 
mean total cost per patient was significantly higher in 
the TC group, £9052 (US$14,531) compared with £7102 
(US$11,399) (p < 0.001). In addition, the mean QALY 
gained per patient over 24 months was significantly 
greater in the FRA group (0.1914) compared with the TC 
group (0.0522). Because the FRA proved to be less expen-
sive and increased QALYs compared with a TC, an ICER 
was not necessary. Finally, using the human capital ap-
proach to cost productivity, total gross mean earnings in 
the 2 postoperative years were £7456 (US$11,968) in the 
TC group and £14,517 (US$23,303) in the FRA group. A 
higher percentage of FRA patients had a positive change 
in employment status following surgery compared with 
TC patients (21.6% vs 9.8%), and FRA patients were more 
likely to see an improvement in their salary after surgery. 
The strength of this study lies in its randomized design, 
excellent outcomes data, and comprehensive cost analy-
sis. However, some utility data were missing, requiring 
estimation in the analysis. In addition, a few important 
health care resources were omitted from the cost analysis, 
including radiology costs, medication, outpatient services, 
and primary care costs. The clinical observations of Free-
man et al. are supported by an earlier randomized trial by 
McKenna et al. that found improved clinical outcomes in 
patients implanted with FRA compared with TC.27 These 
authors speculated that the improved pain relief with 
FRA may be due to the more physiological transfer of 
loads as the fusion matures compared with point loading 
with titanium cages. Overall, the study of Freeman et al. 
provides Level II evidence that the use of femoral ring al-
lograft for lumbar interbody fusion is more cost-effective 
than the use of a specific titanium cage when performing 
a posterolateral circumferential fusion (see Table 1).
Cost-Effectiveness of rhBMP
Cahill et al. reviewed a retrospective cohort of 
328,468 patients undergoing lumbar fusion procedures 
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from 2002 to 2006, selected from the Nationwide Inpa-
tient Sample database, in an effort to determine the cost 
associated with the application of recombinant human 
bone morphogenetic protein (rhBMP) as a fusion en-
hancer.7 The usage of rhBMP has increased from 0.69% 
of all fusions in 2002 to 24.89% of all fusions in 2006. 
The primary outcome measures included the rate of rh-
BMP utilization, complications, length of stay, and asso-
ciated hospital charges. There were no differences in the 
rates of overall complications based on the application of 
rhBMP. The use of rhBMP was associated with an ex-
tended hospitalization (3.17% increase). The utilization 
of rhBMP was associated with a 20% increase in total 
hospital charges compared with those undergoing fusion 
without rhBMP ($74,254 vs $57,393). This analysis, how-
ever, is limited by the lack of clinical outcome data, and 
since only total hospital charges were considered, with a 
wide range in charges identified between different institu-
tions, $54,737–$102,663 for lumbar fusions supplemented 
with rhBMP and $39,660–$83,608 when rhBMP was not 
included. This study provides Level IV evidence that rh-
BMP is associated with increased length of hospital stay 
(LOS) and total hospital charges in all categories of spi-
nal fusion (see Table 1).
Glassman et al. conducted a randomized trial of rh-
BMP-2 versus iliac crest bone graft (ICBG) in patients 
over 60 years of age undergoing either single-level or mul-
tilevel instrumented posterolateral lumbar fusion.20 Out-
comes were measured up to 2 years after surgery utiliz-
ing validated outcomes instruments, including the ODI, 
SF-36, and numerical pain scales. Direct costs were ob-
tained from actual reimbursement to the hospital. Where 
actual payments could not be determined, a Medicare fee 
schedule was used to assign direct cost. No significant 
differences in any of the outcome measures were identi-
fied between the 2 treatment groups. However, the fusion 
rate at 2 years, as measured by CT and presence of bridg-
ing bone, was significantly higher in the rhBMP-2 group 
(86.3% vs 70.8%, p = 0.030). Including revision surgery 
and outpatient costs (i.e., postoperative rehabilitation), the 
total cost of care over 2 years was not significantly differ-
ent for 2 groups ($42,574 for the ICBG group vs $40,131 
for the rhBMP-2 group). This study provides Level IV 
evidence that either ICBG or rhBMP-2 may be considered 
as posterolateral fusion graft options in patients over the 
age of 60 (see Table 1).
Using the same data as Glassman et al., Carreon et 
al. performed a cost-utility analysis of rhBMP-2 versus 
ICBG.8 Utility was estimated from the SF-6D.4 As de-
scribed above, costs were determined from actual reim-
bursement to hospitals and physicians participating in the 
trial and included reimbursement for inpatient and out-
patient services, radiographic imaging, and medications. 
There was no significant difference in change in utility 
between the 2 groups at any time point. The total cost of 
using rhBMP-2 was $39,967, with a 0.11 mean improve-
ment in SF-6D; for ICBG, the cost was $42,286, with a 
mean improvement of 0.10 in SF-6D. The authors failed 
to account for indirect costs such as lost wages or out-of-
pocket expenses. This study provides Level IV evidence 
that the cost of using rhBMP-2 is comparable to the cost 
of autograft for patients undergoing lumbar fusion sur-
gery (see Table 1).
Alt et al. performed a cost analysis on a previously 
studied cohort of patients who either received rhBMP-2 
or ICBG during lumbar fusion.2,6 The study population 
included 279 patients randomized to either rhBMP-2 or 
ICBG and 400 patients from a prospective nonrandom-
ized cohort. The original trial demonstrated significant 
reduction in surgery time (reduction of 54 minutes) and 
blood loss (reduction of 66 ml) when rhBMP-2 was used 
instead of ICBG. Patients in the rhBMP-2 group required 
fewer revision operations and returned to work earlier. Fi-
nally, the fusion rate and clinical outcomes of patients in 
the rhBMP-2 group were significantly better than those in 
the ICBG group. The authors performed a retrospective 
cost analysis from data collected in 3 countries: Germa-
ny, France, and the United Kingdom (UK). Direct costs 
were estimated from the expense associated with the use 
of rhBMP-2, operating room time, and revision surgery. 
Indirect costs were estimated from the loss of productiv-
ity and the national average of gross wages. From a soci-
etal perspective, the overall savings associated with use of 
rhBMP-2 compared with ICBG for Germany, France, and 
the UK were €8483 (US$11,745), €9191 (US$12,726), 
and €8783 (US$12,161), respectively. This study is lim-
ited by the retrospective study design and failure to ac-
count for costs associated with out-of-pocket expenses, 
medications, or outpatient treatment. This study provides 
Level IV evidence that the use of rhBMP-2 is associated 
with a reduction in return-to-work time and may increase 
productivity from a societal perspective.
Conflicting Data Regarding the Cost-Effectiveness of  
Cell-Salvage Autotransfusion
Savvidou et al. randomized 50 patients undergoing 
instrumented lumbar fusion to a group that received cell-
salvage autotransfusion and a group that did not.34 The 
total amount of allogeneic and cell-salvage blood used 
per patient was recorded. The cost for each unit of allo-
geneic blood (€450 [US$623]) versus cell-salvage blood 
(€370 [US$512]) was determined from the Greek minis-
try of health. The total transfusion cost in the group that 
received cell-salvage autotransfusion was significantly 
lower than the group that did not (€995 [US$1377] versus 
€1220 [US$1689], p < 0.05). Because this study did not 
measure outcomes, it is impossible to perform an adequate 
cost-effectiveness analysis regarding the use of autotrans-
fusion. This study provides Level IV evidence that the use 
of cell-salvage autotransfusion lowered the costs of trans-
fusing blood for elective lumbar fusions (see Table 1).
Reitman et al. performed a retrospective analysis of 
patients who had undergone instrumented lumbar fusion 
with and without cell-salvage autotransfusion.30 There 
was no significant difference in blood loss between the 2 
groups, and 38% of the blood in the study group was re-
turned as cell-salvage autotransfusion. The average charge 
of the cell-salvage was $512 per patient compared with 
$270 per patient in the control group. The authors con-
cluded that the cost of blood replacement was higher in the 
cell-salvage autotransfusion group. As with other studies 
investigating the application of cell-salvage autotransfu-
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sion, there are insufficient data to perform a meaningful 
cost-effectiveness analysis. This study provides Level IV 
evidence that use of cell-salvage autotransfusion is more 
costly than normal postoperative transfusion (see Table 1).
Summary
Lumbar fusion for certain degenerative spine disor-
ders can be effective in improving clinical outcomes and 
long-term quality of life when compared with nonoperative 
therapy. Comprehensive economic analyses that include 
long-term clinical outcomes data and both direct and indi-
rect costs will be necessary before any recommendations 
can be made regarding the cost-effectiveness of various 
methods of lumbar fusion. Given the significant impact of 
lumbar degenerative disease, it is essential from a societal 
perspective that these studies be conducted. Recent cost-
analyses have demonstrated the long-term benefits of cir-
cumferential fusions over posterolateral fusions, FRA over 
TC when performing an interbody fusion, and that both 
rhBMP-2 and ICBG are associated with similar costs.
Key Issues for Future Investigation
As new technologies for lumbar fusion are introduced 
and studies are performed to assess their effectiveness, 
the inclusion of an economic analysis is essential. Appro-
priate long-term follow-up is important when designing 
trials, as the benefits of lumbar fusion, both clinically and 
economically, may be apparent several years following 
the operation. The major challenge for investigators is to 
determine the most reliable estimate of cost. Medicare re-
imbursement may underestimate real costs, and medical 
charges may grossly overestimate true costs. New meth-
odology is needed to allow for meaningful long-term as-
sessment of health cost, and it may be that the best “labo-
ratory” for these studies is a well-run health care system 
that follows costs directly along with patient outcomes as 
a matter of course.
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